Drug Keytruda May Help Block Melanoma's Return
The drug also gained attention after former President Jimmy Carter announced in 2015 that Keytruda had beaten back his brain cancer.
A new study into U.S. cancer data finds that checkpoint blockade immunotherapy doubles median overall survival in melanoma patients with brain metastases.
There has been welcome excitement in the cancer field lately about immune-based treatments, which co-opt the body’s own immune system to fight tumors. The so-called immunotherapies have transformed everything from solid cancers like melanoma and lung, to blood cancers like lymphoma and leukemia. In the latest study involving one of the first immunotherapies approved by the Food and Drug Administration, researchers report that an immune-based approach can even help people with advanced melanoma, which has spread to the brain, to live longer. The study, published in Cancer Immunology Research, included more than 2,700 ...
A therapy that harnesses the body’s immune system to target and destroy cancer cells has been found to help people with melanoma that has spread to the brain.
THURSDAY, July 12, 2018 -- A type of therapy that harnesses the immune system is giving new hope to people battling a once hopeless cancer -- melanoma that's spread to the brain. New research involving more than 2,700 U.S. patients is confirming...
(Brigham and Women's Hospital) A new study evaluates data from more than 1,500 cancer programs across the country to determine the effectiveness of checkpoint blockade immunotherapies, finding that these therapies provided significant improvements in overall survival for patients with melanoma brain metastases.
(American Association for Cancer Research) Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.
Publication date: January 2018Source: Advances in Biological Regulation, Volume 67Author(s): Fumio Sakane, Satoru Mizuno, Daisuke Takahashi, Hiromichi SakaiAbstractDiacylglycerol kinase (DGK) phosphorylates diacylglycerol (DG) to produce phosphatidic acid (PA). Mammalian DGK comprises ten isozymes (α–κ) and regulates a wide variety of physiological and pathological events, such as cancer, type II diabetes, neuronal disorders and immune responses. DG and PA consist of various molecular species that have different acyl chains at the sn-1 and sn-2 positions, and consequently, mammalian cells contain at least...
ConclusionWe report the clinical and genomic landscape of a patient with MPTs who had no identifiable unique somatic or germline mutations to explain her predilection to cancer. The treatment course and overall prognosis for this patient is important for understanding future cases with unrelated, metachronous MPTs, the occurrence of which cannot always be explained by underlying genetic mechanisms.
Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance.